Towards a new combination therapy for tuberculosis with next generation benzothiazinones
Abstract The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo‐enzyme DprE1, decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase. Here, we synthesized a new series of piperazine‐containing benzothiazinones (PBTZ) and show that, like BTZ043, the prec...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer Nature
2014-02-01
|
| Seri Bilgileri: | EMBO Molecular Medicine |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/emmm.201303575 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|